Fig. 1From: Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesotheliomaPhotographs of described skin changes after 6 weeks of ipilimumab/pembrolizumab combination therapy. a–c Broken livedoid type skin changes symmetrically distributed in all four limbs. d A prominent area of purpura on the left halluxBack to article page